Background And Purpose: To describe the implementation and to evaluate the results of direct segment aperture optimization using the segment outline and weight adapting tool (SOWAT) in intensity-modulated radiotherapy (IMRT) for prostate cancer.
Patients And Methods: 14 consecutive, unselected patients with localized prostate cancer were entered in a planning study comparing IMRT without and with the use of SOWAT. The clinical target volume (CTV) consisted of the prostate and seminal vesicles in all cases. To create the planning target volume (PTV), a three-dimensional anisotropic margin (10 mm in craniocaudal direction, 7 mm in both other directions) was used. To compare both plans, physical as well as biological endpoints were considered.
Results: Considering the CTV, SOWAT resulted in a significantly higher minimal dose together with a higher dose to 95% (D(95)) and 90% (D(90)) of the CTV volume (p < 0.05; Figure 2). Target dose homogeneity was significantly improved (p < 0.001). Tumor control probability (TCP) was significantly increased (p < 0.05). Considering the PTV, D(90) was significantly increased (p < 0.05). Target dose homogeneity was significantly improved (p < 0.05; Figure 1). For rectum, the volumes receiving 50 Gy (R(vol50)), 60 Gy (R(vol60)), or 65 Gy (R(vol65)) as well as the mean dose were significantly lowered after SOWAT (p = 0.0001; Figure 3). Rectal normal tissue complication probability (NTCP) was significantly lower after SOWAT (p = 0.005). Probability of uncomplicated local control (P+) was significantly higher after SOWAT (p < 0.0001).
Conclusion: SOWAT is a powerful planning tool to increase the therapeutic ratio of IMRT for prostate cancer. It leaves the delivery time unchanged, so that treatments can still be delivered within a time slot of 8 min.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00066-004-1209-2 | DOI Listing |
J Clin Oncol
January 2025
Fred Saad, MD, University of Montreal, Montreal, QC, Canada; Egils Vjaters, MD, P. Stradinš Clinical University Hospital, Riga, Latvia; Isabella Testa, MD, Bayer S.p.A, Milan, Italy; and Kunhi Parambath Haresh, MD, All India Institute of Medical Sciences, New Delhi, India.
J Clin Oncol
January 2025
Abhenil Mittal, MD, DM, MBBS and Geordie Linford, MD, MSc, BSc, Department of Oncology, Northeast Cancer Center, Health Sciences North, Sudbury, ON, Canada, Division of Clinical Sciences, Northern Ontario School of Medicine, ON, Canada; and Bishal Gyawali, MD, PhD, FASCO, Department of Oncology, Queen's University, Kingston, ON, Canada, Department of Public Health Sciences, Queen's University, Kingston, ON, Canada, Division of Cancer Care and Epidemiology, Queen's University, Kingston, ON, Canada.
PLoS One
January 2025
UVSQ, Inserm, Gustave Roussy, CESP, Université Paris-Saclay, Villejuif, France.
Background: Prostate cancer remains the most frequent cancer among men, representing a significant health burden. Despite its high morbidity and mortality rates, the etiology of prostate cancer remains relatively unknown, with only non-modifiable established risk factors. Chronic inflammation has emerged as a potential factor in prostate carcinogenesis.
View Article and Find Full Text PDFJ Med Chem
January 2025
Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
Precise surgical resection of prostate cancer (PCa) is a significant clinical challenge due to the impact of positive surgical margins on postoperative outcomes. Fluorescence-guided surgery (FGS) enables real-time tumor visualization using fluorescent probes. In this study, we synthesized and evaluated an indocyanine green (ICG)-based PSMA-targeted near-infrared probe, , for intraoperative imaging of PCa lesions.
View Article and Find Full Text PDFJ Zhejiang Univ Sci B
January 2025
Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!